GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hansa Biopharma AB (OSTO:HNSA) » Definitions » Asset Turnover

Hansa Biopharma AB (OSTO:HNSA) Asset Turnover : 0.05 (As of Sep. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Hansa Biopharma AB Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Hansa Biopharma AB's Revenue for the three months ended in Sep. 2024 was kr48.7 Mil. Hansa Biopharma AB's Total Assets for the quarter that ended in Sep. 2024 was kr985.0 Mil. Therefore, Hansa Biopharma AB's Asset Turnover for the quarter that ended in Sep. 2024 was 0.05.

Asset Turnover is linked to ROE % through Du Pont Formula. Hansa Biopharma AB's annualized ROE % for the quarter that ended in Sep. 2024 was 154.13%. It is also linked to ROA % through Du Pont Formula. Hansa Biopharma AB's annualized ROA % for the quarter that ended in Sep. 2024 was -42.15%.


Hansa Biopharma AB Asset Turnover Historical Data

The historical data trend for Hansa Biopharma AB's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hansa Biopharma AB Asset Turnover Chart

Hansa Biopharma AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.01 0.03 0.11 0.10

Hansa Biopharma AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.05 0.06 0.04 0.05

Competitive Comparison of Hansa Biopharma AB's Asset Turnover

For the Biotechnology subindustry, Hansa Biopharma AB's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hansa Biopharma AB's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hansa Biopharma AB's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Hansa Biopharma AB's Asset Turnover falls into.



Hansa Biopharma AB Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Hansa Biopharma AB's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=134.094/( (1687.406+1018.041)/ 2 )
=134.094/1352.7235
=0.10

Hansa Biopharma AB's Asset Turnover for the quarter that ended in Sep. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Sep. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Sep. 2024 ))/ count )
=48.664/( (1029.376+940.675)/ 2 )
=48.664/985.0255
=0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Hansa Biopharma AB  (OSTO:HNSA) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Hansa Biopharma AB's annulized ROE % for the quarter that ended in Sep. 2024 is

ROE %**(Q: Sep. 2024 )
=Net Income/Total Stockholders Equity
=-415.184/-269.3765
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-415.184 / 194.656)*(194.656 / 985.0255)*(985.0255/ -269.3765)
=Net Margin %*Asset Turnover*Equity Multiplier
=-213.29 %*0.1976*-3.6567
=ROA %*Equity Multiplier
=-42.15 %*-3.6567
=154.13 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) net income data. The Revenue data used here is four times the quarterly (Sep. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Hansa Biopharma AB's annulized ROA % for the quarter that ended in Sep. 2024 is

ROA %(Q: Sep. 2024 )
=Net Income/Total Assets
=-415.184/985.0255
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-415.184 / 194.656)*(194.656 / 985.0255)
=Net Margin %*Asset Turnover
=-213.29 %*0.1976
=-42.15 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) net income data. The Revenue data used here is four times the quarterly (Sep. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Hansa Biopharma AB Asset Turnover Related Terms

Thank you for viewing the detailed overview of Hansa Biopharma AB's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Hansa Biopharma AB Business Description

Traded in Other Exchanges
Address
Scheelevagen 22, Lund, SWE, 223 63
Hansa Biopharma AB is a biopharmaceutical company that develops immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, and cancer. The company's product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in sensitized patients and further developed for use in other organ and tissue transplantation as well as acute autoimmune indications. It operates in Sweden, other European countries, and the U.S. The group generates the majority of its revenue from product sales.

Hansa Biopharma AB Headlines

No Headlines